EA200501101A1 - Способ получения рекомбинантных поликлональных белков - Google Patents
Способ получения рекомбинантных поликлональных белковInfo
- Publication number
- EA200501101A1 EA200501101A1 EA200501101A EA200501101A EA200501101A1 EA 200501101 A1 EA200501101 A1 EA 200501101A1 EA 200501101 A EA200501101 A EA 200501101A EA 200501101 A EA200501101 A EA 200501101A EA 200501101 A1 EA200501101 A1 EA 200501101A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- collection
- library
- nucleic acid
- recombinant polyclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Abstract
Настоящее изобретение относится к способу производства композиции рекомбинантного поликлонального белка, в особенности композиции рекомбинантного поликлонального антитела. Способ предусматривает получение коллекции клеток, трансфицированных библиотекой вариантных последовательностей нуклеиновой кислоты, в котором каждая клетка в коллекции трансфицирована и способна к экспрессии одного элемента библиотеки, который кодирует определенный элемент поликлонального белка, который связывает специфический антиген и который расположен на том же отдельном сайте в геноме отдельных клеток в указанной коллекции, в котором указанная последовательность нуклеиновой кислоты в природе не связана с указанной клеткой в коллекции. Клетки культивируют при подходящих условиях для экспрессии поликлонального белка, который получают из супернатанта культуры или клеток. Последовательность нуклеиновой кислоты вводят в клетки посредством трансфекции библиотекой векторов для сайт-специфичной интеграции. Настоящий способ подходит для производства рекомбинантных поликлональных антител, что, таким образом, делает возможной описанную выше замену полученных из плазмы терапевтических продуктов иммуноглобулина.Отчет о международном поиске был опубликован 2004.11.04.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43840303P | 2003-01-07 | 2003-01-07 | |
DKPA200300008 | 2003-01-07 | ||
US47601803P | 2003-06-05 | 2003-06-05 | |
PCT/DK2004/000001 WO2004061104A2 (en) | 2003-01-07 | 2004-01-07 | Method for manufacturing recombinant polyclonal proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501101A1 true EA200501101A1 (ru) | 2006-02-24 |
EA013225B1 EA013225B1 (ru) | 2010-04-30 |
Family
ID=32718469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501101A EA013225B1 (ru) | 2003-01-07 | 2004-01-07 | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
Country Status (19)
Country | Link |
---|---|
US (1) | US9163232B2 (ru) |
EP (2) | EP1583830B1 (ru) |
JP (2) | JP4589914B2 (ru) |
KR (1) | KR101024443B1 (ru) |
AT (1) | ATE338816T1 (ru) |
AU (1) | AU2004203727C1 (ru) |
BR (1) | BRPI0406678A (ru) |
CA (1) | CA2512647C (ru) |
DE (1) | DE602004002275T2 (ru) |
DK (1) | DK1583830T3 (ru) |
EA (1) | EA013225B1 (ru) |
ES (1) | ES2273202T3 (ru) |
HK (1) | HK1078896A1 (ru) |
IL (1) | IL169101A (ru) |
MX (1) | MXPA05006724A (ru) |
NZ (1) | NZ541458A (ru) |
PT (1) | PT1583830E (ru) |
SI (1) | SI1583830T1 (ru) |
WO (1) | WO2004061104A2 (ru) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
BRPI0406678A (pt) | 2003-01-07 | 2005-12-20 | Symphogen As | Método para produzir proteìnas policlonais recombinantes |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
CA2574062A1 (en) * | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
DE602005016818D1 (de) * | 2004-07-20 | 2009-11-05 | Symphogen As | Verfahren zur charakterisierung einer polyklonalen zellinie |
CA2613471C (en) * | 2005-06-24 | 2016-09-06 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
EP1966241A2 (en) | 2005-12-05 | 2008-09-10 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
JP2009528828A (ja) * | 2006-03-06 | 2009-08-13 | シムフォゲン・アクティーゼルスカブ | 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 |
US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
FR2910490B1 (fr) * | 2006-12-20 | 2012-10-26 | Lab Francais Du Fractionnement | Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques |
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
WO2008097926A2 (en) * | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
TW200846362A (en) * | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
NZ578943A (en) | 2007-03-01 | 2012-09-28 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
EP2121920B1 (en) | 2007-03-01 | 2011-08-24 | Symphogen A/S | Method for cloning cognate antibodies |
CA2678628A1 (en) | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
ATE481483T1 (de) * | 2007-05-25 | 2010-10-15 | Symphogen As | Verfahren zur herstellung eines rekombinanten polyklonalen proteins |
MY150621A (en) | 2007-08-30 | 2014-02-14 | Daiichi Sankyo Co Ltd | Anti-epha2 antibody |
EP2244735A4 (en) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
PL2206727T3 (pl) | 2007-10-11 | 2015-08-31 | Daiichi Sankyo Co Ltd | Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami |
SG189793A1 (en) * | 2008-04-23 | 2013-05-31 | Symphogen As | Methods for manufacturing a polyclonal protein |
JP5719298B2 (ja) | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組換え抗上皮増殖因子受容体抗体組成物 |
WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
JP5653909B2 (ja) | 2009-04-09 | 2015-01-14 | 第一三共株式会社 | 抗Siglec−15抗体 |
AU2010306563B2 (en) | 2009-10-15 | 2013-11-28 | Circle 33, Llc | Antibody therapeutics with local activity in the digestive tract |
NZ623347A (en) | 2010-10-29 | 2014-07-25 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
CA2816520C (en) | 2010-11-01 | 2017-11-21 | Symphogen A/S | Anti-her3 antibodies and compositions |
AU2011329872B2 (en) | 2010-11-16 | 2017-04-13 | Excelimmune, Inc. | Methods for producing recombinant proteins |
PL2703486T3 (pl) | 2011-04-25 | 2018-07-31 | Daiichi Sankyo Company, Limited | Przeciwciało anty-b7-h3 |
ES2791758T3 (es) | 2011-12-22 | 2020-11-05 | Hoffmann La Roche | Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
TW201343672A (zh) | 2012-03-30 | 2013-11-01 | Daiichi Sankyo Co Ltd | Cdr經修飾之抗siglec-15抗體 |
TW201345925A (zh) | 2012-03-30 | 2013-11-16 | Daiichi Sankyo Co Ltd | 新穎抗siglec-15抗體 |
SG10201608382QA (en) | 2012-04-09 | 2016-12-29 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
CN114163530A (zh) | 2012-04-20 | 2022-03-11 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
PL2841457T3 (pl) | 2012-04-27 | 2019-09-30 | Daiichi Sankyo Company, Limited | Przeciwciało anty-ROBO4 |
CN104428318B (zh) | 2012-05-02 | 2018-09-25 | 西福根有限公司 | 人源化泛her抗体组合物 |
JP2015163047A (ja) * | 2012-06-20 | 2015-09-10 | 国立大学法人 東京大学 | タンパク質の迅速改良法 |
BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
PL2900694T3 (pl) | 2012-09-27 | 2018-12-31 | Merus N.V. | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス, インコーポレイテッド | トランスサイレチン抗体およびその使用 |
EP3835422A1 (en) | 2013-09-30 | 2021-06-16 | Daiichi Sankyo Company, Limited | Anti-lps o11 antibody |
JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
WO2015093925A1 (es) * | 2013-12-19 | 2015-06-25 | CASTRO ALDRETE, Jorge Isaac | Método de producción de anticuerpos específicos |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
ES2904573T3 (es) | 2015-03-27 | 2022-04-05 | Univ Southern California | Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos |
CA2987992A1 (en) | 2015-06-04 | 2016-12-08 | University Of Southern California | Lym-1 and lym-2 targeted car cell immunotherapy |
CA2991880A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
KR20180053744A (ko) | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
AU2016325858B2 (en) | 2015-09-24 | 2022-05-26 | Daiichi Sankyo Company, Limited | Anti-GARP antibody |
CN115925944A (zh) | 2015-10-23 | 2023-04-07 | 美勒斯公司 | 抑制癌症生长的结合分子 |
WO2017205014A1 (en) * | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
CA3048174A1 (en) | 2016-12-22 | 2018-06-28 | Daiichi Sankyo Company, Limited | Anti-cd3 antibody and molecules comprising the antibody |
AU2018218753A1 (en) | 2017-02-07 | 2019-09-26 | Daiichi Sankyo Company, Limited | Anti-GPRC5D antibody and molecule containing same |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
EA201992350A1 (ru) | 2017-04-05 | 2020-03-23 | Симфоген А/С | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 |
CN110913905A (zh) | 2017-06-30 | 2020-03-24 | 国立大学法人北海道大学 | 不产生生长障碍的小儿骨质疏松症治疗药 |
TW202402805A (zh) | 2017-07-27 | 2024-01-16 | 日商第一三共股份有限公司 | 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法 |
EP3665198A1 (en) | 2017-08-09 | 2020-06-17 | Merus N.V. | Antibodies that bind egfr and cmet |
CN111447952A (zh) | 2017-10-05 | 2020-07-24 | 第一三共株式会社 | 用于细胞毒性t细胞耗竭的组合物 |
US11795579B2 (en) | 2017-12-11 | 2023-10-24 | Abalone Bio, Inc. | Yeast display of proteins in the periplasmic space |
JP7125979B2 (ja) | 2018-03-05 | 2022-08-25 | 学校法人 埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
JP6790307B2 (ja) | 2018-05-31 | 2020-11-25 | 第一三共株式会社 | 抗ヒトtlr7抗体 |
CN112513074A (zh) | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
CN112673023B (zh) | 2018-07-10 | 2023-09-12 | 国立大学法人神户大学 | 抗SIRPα抗体 |
KR20210040059A (ko) | 2018-07-27 | 2021-04-12 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 약물 부위를 인식하는 단백질 |
US20220267453A1 (en) | 2019-07-26 | 2022-08-25 | Saitama Medical University | Antibody recognizing extracellular region of alk2/acvr1 |
EP4049675A4 (en) | 2019-10-25 | 2023-11-22 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOREGULATOR |
AU2020416989A1 (en) | 2019-12-31 | 2022-08-25 | Antagonis | Compositions and methods for the prevention of S. Aureus Infection |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
US11975066B2 (en) | 2020-08-31 | 2024-05-07 | SAB Biotherapeutics, Inc. | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US155114A (en) * | 1874-09-15 | Improvement in methods of laying and forming cast-iron pipes | ||
CA1293460C (en) * | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
EP0530216A4 (en) | 1990-04-19 | 1993-06-30 | Medimmune, Inc. | Administration of monoclonal antibodies against respiratory viruses |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
WO1992015694A1 (en) * | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
DK0744958T3 (da) * | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
RO120148B1 (ro) * | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
US6368821B1 (en) | 1997-04-14 | 2002-04-09 | Stratagene | Process for infecting eukaryotic cells with a bacterial virus |
US6632672B2 (en) * | 1998-08-19 | 2003-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for genomic modification |
US20020155114A1 (en) | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
EP1194540A1 (en) | 1999-07-14 | 2002-04-10 | Clontech Laboratories Inc. | Recombinase-based methods for producing expression vectors and compositions for use in practicing the same |
JP4808880B2 (ja) | 1999-07-23 | 2011-11-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | バクテリオファージphic31組み換え系による真核細胞におけるdna組み換え |
NZ522605A (en) * | 2000-05-26 | 2005-03-24 | Symphogen As | Recombinant or purified polyclonal antibodies for treating allergy |
WO2001094571A1 (fr) | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Vecteur d'expression permettant le criblage de cellules a haute expression de proteine de recombinaison, transformant a haute expression de proteine de recombinaison, et leur utilisation |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
US6610472B1 (en) * | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
WO2002044361A2 (en) * | 2000-11-28 | 2002-06-06 | Applied Molecular Evolution, Inc. | Eukaryotic expression libraries based on double lox recombination and methods of use |
US20030044398A1 (en) | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
AU2003283995A1 (en) | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
BRPI0406678A (pt) | 2003-01-07 | 2005-12-20 | Symphogen As | Método para produzir proteìnas policlonais recombinantes |
US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
WO2005070962A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
DE602005016818D1 (de) | 2004-07-20 | 2009-11-05 | Symphogen As | Verfahren zur charakterisierung einer polyklonalen zellinie |
CA2574062A1 (en) | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
EP1966241A2 (en) | 2005-12-05 | 2008-09-10 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
JP2009528828A (ja) | 2006-03-06 | 2009-08-13 | シムフォゲン・アクティーゼルスカブ | 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 |
TW200846362A (en) | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
ATE481483T1 (de) | 2007-05-25 | 2010-10-15 | Symphogen As | Verfahren zur herstellung eines rekombinanten polyklonalen proteins |
-
2004
- 2004-01-07 BR BR0406678-2A patent/BRPI0406678A/pt not_active Application Discontinuation
- 2004-01-07 ES ES04700438T patent/ES2273202T3/es not_active Expired - Lifetime
- 2004-01-07 DK DK04700438T patent/DK1583830T3/da active
- 2004-01-07 AT AT04700438T patent/ATE338816T1/de active
- 2004-01-07 DE DE602004002275T patent/DE602004002275T2/de not_active Expired - Lifetime
- 2004-01-07 EA EA200501101A patent/EA013225B1/ru not_active IP Right Cessation
- 2004-01-07 CA CA2512647A patent/CA2512647C/en not_active Expired - Fee Related
- 2004-01-07 MX MXPA05006724A patent/MXPA05006724A/es active IP Right Grant
- 2004-01-07 EP EP04700438A patent/EP1583830B1/en not_active Expired - Lifetime
- 2004-01-07 JP JP2006500508A patent/JP4589914B2/ja not_active Expired - Fee Related
- 2004-01-07 AU AU2004203727A patent/AU2004203727C1/en not_active Ceased
- 2004-01-07 EP EP06018504A patent/EP1762617A1/en not_active Withdrawn
- 2004-01-07 KR KR1020057012745A patent/KR101024443B1/ko not_active IP Right Cessation
- 2004-01-07 NZ NZ541458A patent/NZ541458A/en not_active IP Right Cessation
- 2004-01-07 WO PCT/DK2004/000001 patent/WO2004061104A2/en active IP Right Grant
- 2004-01-07 PT PT04700438T patent/PT1583830E/pt unknown
- 2004-01-07 SI SI200430074T patent/SI1583830T1/sl unknown
-
2005
- 2005-06-09 IL IL169101A patent/IL169101A/en not_active IP Right Cessation
- 2005-11-25 HK HK05110692A patent/HK1078896A1/xx not_active IP Right Cessation
-
2008
- 2008-12-19 US US12/339,490 patent/US9163232B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155716A patent/JP2010268806A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL169101A (en) | 2009-02-11 |
ES2273202T3 (es) | 2007-05-01 |
WO2004061104A3 (en) | 2004-11-04 |
WO2004061104A2 (en) | 2004-07-22 |
CA2512647A1 (en) | 2004-07-22 |
BRPI0406678A (pt) | 2005-12-20 |
KR20050101538A (ko) | 2005-10-24 |
CA2512647C (en) | 2013-10-08 |
EP1583830A2 (en) | 2005-10-12 |
AU2004203727B2 (en) | 2008-01-31 |
KR101024443B1 (ko) | 2011-03-23 |
DE602004002275D1 (de) | 2006-10-19 |
EP1583830B1 (en) | 2006-09-06 |
EA013225B1 (ru) | 2010-04-30 |
NZ541458A (en) | 2006-04-28 |
HK1078896A1 (en) | 2006-03-24 |
US9163232B2 (en) | 2015-10-20 |
JP2006515520A (ja) | 2006-06-01 |
MXPA05006724A (es) | 2005-09-08 |
ATE338816T1 (de) | 2006-09-15 |
AU2004203727A1 (en) | 2004-07-22 |
AU2004203727C1 (en) | 2008-08-21 |
JP2010268806A (ja) | 2010-12-02 |
DE602004002275T2 (de) | 2007-09-06 |
SI1583830T1 (sl) | 2006-12-31 |
PT1583830E (pt) | 2006-11-30 |
US20090136498A1 (en) | 2009-05-28 |
JP4589914B2 (ja) | 2010-12-01 |
DK1583830T3 (da) | 2007-01-15 |
EP1762617A1 (en) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501101A1 (ru) | Способ получения рекомбинантных поликлональных белков | |
EA200700249A1 (ru) | Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения | |
CN104854133B (zh) | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 | |
DK2152872T3 (da) | Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein | |
CN104011080B (zh) | 用于真核细胞的全长抗体展示***及其用途 | |
Kurosawa et al. | Rapid production of antigen-specific monoclonal antibodies from a variety of animals | |
NO20020861D0 (no) | PD-1, en reseptor for B7-4, og anvendelser derav | |
Tchoudakova et al. | High level expression of functional human IgMs in human PER. C6® cells | |
DE60039596D1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
CN105602960A (zh) | 抗体的快速人源化 | |
NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
CN109810188A (zh) | 用于克隆和表达关联抗体可变区基因区段的快速方法 | |
DE60144021D1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
Kangro et al. | Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura | |
Russo et al. | Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development | |
Price et al. | Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas | |
ES2440777T3 (es) | Vectores basados en anticuerpo anti-il-12, células huéspedes y métodos de producción y usos | |
US8663980B2 (en) | Vectors, host cells, and methods of production and uses | |
CN106478773A (zh) | 一种人工合成的新型信号肽 | |
CN104558181A (zh) | 靶向b淋巴瘤细胞的人源单链抗体 | |
ES2700442T3 (es) | Método para producir anticuerpos | |
WO2009086352A2 (en) | Cynomolgus toll-like receptor 3 | |
CN106478774A (zh) | 一种用于蛋白质表达的信号肽 | |
CN104558180B (zh) | 靶向t淋巴细胞的人源单链抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |